Scientific topics
Keywords
ITMO
Marc G Berger Prof, MD, PhD, Head of Hematology (Biology) Department
Course and current status
Course and current status
Education:
From 2005: Professor of Hematology (Biology), Auvergne University, Clermont-Ferrand, France
2002: Research Director Accreditation (Habilitation à Diriger des Recherches), Auvergne University, Clermont-Ferrand, France
1997: Sciences thesis (PhD degree)
1991: Diploma of Further Studies (Diplôme d’Etudes Approfondies) in Cellular and Molecular Biology), Auvergne University, Clermont-Ferrand, France
1986-1990: Master’s degree (MD) in Biology, Medical School, Auvergne University, Clermont-Ferrand, France.
1978-1986: MD in General Medicine, Medical School, University of Limoges
Post doctoral training:
June 1997 to September 1998: Post-doctoral fellowship, Terry Fox Laboratory, BCCA, Vancouver, BC, Canada.
Academic appointments:
From 2003: Head of Hematology (Biology)/Immunology Department, University Hospital Center, Clermont-Ferrand, France
1995-2002: MD, Laboratory of Hematology, Hôtel-Dieu, University Hospital Center, Clermont-Ferrand, France
1991-1994: Assistant Professor, Auvergne University and University Hospital Center, Clermont-Ferrand, France
1985-1990: Resident in Medicine, Clermont-Ferrand, France
Other expert activities:
Furthermore, M Berger is an expert in Gaucher disease and has been a member of the Gaucher Disease Treatment Evaluation Committee (Comité d’Evaluation du Traitement de la Maladie de Gaucher) since 2007.
Scientific summary
Scientific summary
M Berger acquired his current expertise in hematopoiesis whilst working as Assistant Professor in the Hematology (Biology) department, developing cellular biology techniques suitable for studying immature hematopoietic cells used mainly for cell therapy. In close collaboration with pediatricians and adult hematologists, he has contributed to improve graft collection and cryopreservation and evaluating the interest of CD34+ immunoselection. The post-doctoral fellowship he pursued in Prof. C. Eaves laboratory (Vancouver, Canada) furthered his knowledge of the most primitive hematopoietic stem cell compartment. On returning to France, he set up a research platform in the laboratory for identifying and selecting rare stem cells (cell culture and flow cytometry). The team then developed research into mesenchymal stem cells from normal bone marrow.
Since becoming part of the Cancer Resistance Exploring and Targeting (CREAT) team led by Prof. P Verrelle, we have been applying our expertise in hematopoiesis to improving the understanding of treatment resistance mechanisms in Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia by focusing on intrinsic and extrinsic mechanisms of resistance, and by studying the effect of stromal cells on the drug-resistant leukemia cells.
